Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
25 hedge funds and large institutions have $46.3M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
19% less funds holding
Funds holding: 31 → 25 (-6)
28% less capital invested
Capital invested by funds: $64.5M → $46.3M (-$18.2M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$906K |
| 2 |
Millennium Management
New York
|
+$39.6K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$37.6K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.73K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$971K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$145K |
| 3 |
E
Ergoteles
New York
|
-$103K |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$99K |
| 5 |
HF
HRT Financial
New York
|
-$72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
26
HRT Financial
New York
| – | -$72K | -18,298 | Closed |
|
27
Renaissance Technologies
New York
| – | -$42K | -10,667 | Closed |
|
28
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$20K | -5,000 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$6K | -1,426 | Closed |
|
30
JP Morgan Chase
New York
| – | -$1K | -185 | Closed |
|
CMPI Hedge Fund Activity: Q4 2021 in Review
25 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q4 2021, worth a combined $46.3M — down 28% from $64.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CMPI and 1 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $906K. The largest seller was Clough Capital Partners, cutting an estimated $971K.
- 25 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q4 2021, down from 31 in Q3 2021.
- Funds reported $46.3M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 28% quarter-over-quarter.
- 1 fund opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 7 closed out, a net change of -6 holders.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $906K added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Clough Capital Partners, an estimated $971K sold.
Based on aggregated 13F filings for Q4 2021.